Carsten Bokemeyer
Expertise in
27
conditions

Carsten Bokemeyer

25 Martinistrasse Str, 
Hamburg, HH, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
27
conditions
25 Martinistrasse Str, 
Hamburg, HH, DE 

Overview

Carsten Bokemeyer practices practicing medicine in Hamburg, Germany.

Mr. Bokemeyer is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Febrile Neutropenia, Testicular Cancer, Colorectal Cancer, Bone Marrow Transplant, and Orchiectomy.

He is actively involved in clinical research, co-authoring 530 peer reviewed articles and participating in 7 clinical trials.

Gender

Male

Locations

25 Martinistrasse Str, Hamburg, HH, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors
Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors
Enrollment Status: Recruiting
Publish Date: April 13, 2026
Intervention Type: Biological, Device, Drug
Study Drugs: IMA203 Product, Atezolizumab
Study Phase: Phase 1/Phase 2
A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: July 29, 2025
Intervention Type: Drug, Biological
Study Drugs: Cisplatin, Capecitabine, Paclitaxel, Fluorouracil (5-FU), Oxaliplatin, Tislelizumab
Study Phase: Phase 3
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors(ACTengine® IMA202-101)
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors(ACTengine® IMA202-101)
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Device, Drug
Study Drug: IMA202
Study Phase: Phase 1
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors (ACTengine® IMA201-101)
Phase 1 Study Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Recurrent and/or Refractory Solid Tumors (ACTengine® IMA201-101)
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Diagnostic test, Biological
Study Drugs: IMA201, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) As First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Drug, Procedure
Study Drugs: Paclitaxel, Ifosfamide, Cisplatin, Pegylated G-CSF, G-CSF, Carboplatin, Etoposide Phosphate
Study Phase: Phase 3
Phase 2 Study Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell
Phase 2 Study Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell
Enrollment Status: Terminated
Publish Date: February 02, 2024
Intervention Type: Drug
Study Drug: Cabazitaxel
Study Phase: Phase 2
An Investigator Initiated Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor (KPT-330), An Oral Selective Inhibitor Of Nuclear Export (SINE), In Patients With Metastatic Colorectal Cancer
An Investigator Initiated Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor (KPT-330), An Oral Selective Inhibitor Of Nuclear Export (SINE), In Patients With Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: April 08, 2022
Intervention Type: Drug
Study Phase: Phase 1
View 6 Less Clinical Trials

530 Total Publications

Overexpression of the ERG oncogene in prostate cancer identifies candidates for PARP inhibitor-based radiosensitization.
Overexpression of the ERG oncogene in prostate cancer identifies candidates for PARP inhibitor-based radiosensitization.
Journal: The Journal of clinical investigation
Published: February 03, 2026

Frequently Asked Questions about Carsten Bokemeyer

Is Carsten Bokemeyer a top-rated expert for Bone Marrow Transplant?

MediFind is an objective health platform that identifies experts based on real-world data. Carsten Bokemeyer is classified as an Elite expert for Bone Marrow Transplant, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Carsten Bokemeyer participate in research or clinical trials?

Yes. Carsten Bokemeyer has published 530 articles and abstracts on conditions like Bone Marrow Transplant. You can view a list of Carsten Bokemeyer's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Bokemeyer's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 17 Advanced Conditions
View All 78 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile